284 related articles for article (PubMed ID: 34680734)
21.
Guo Y; Han R; Jiang B; Ding L; Yang F; Zheng B; Yang Y; Wu S; Yin D; Zhu D; Hu F;
Microbiol Spectr; 2022 Aug; 10(4):e0185422. PubMed ID: 35862963
[TBL] [Abstract][Full Text] [Related]
22. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams.
Gonçalves-Pereira J; Póvoa P
Crit Care; 2011; 15(5):R206. PubMed ID: 21914174
[TBL] [Abstract][Full Text] [Related]
23. Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy.
Ulldemolins M; Vaquer S; Llauradó-Serra M; Pontes C; Calvo G; Soy D; Martín-Loeches I
Crit Care; 2014 Jun; 18(3):227. PubMed ID: 25042938
[TBL] [Abstract][Full Text] [Related]
24. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic variability of beta-lactams in critically ill patients: A narrative review.
Boidin C; Moshiri P; Dahyot-Fizelier C; Goutelle S; Lefeuvre S
Anaesth Crit Care Pain Med; 2020 Feb; 39(1):87-109. PubMed ID: 31513935
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics, Pharmacodynamics, and Dosing Considerations of Novel β-Lactams and β-Lactam/β-Lactamase Inhibitors in Critically Ill Adult Patients: Focus on Obesity, Augmented Renal Clearance, Renal Replacement Therapies, and Extracorporeal Membrane Oxygenation.
Bakdach D; Elajez R; Bakdach AR; Awaisu A; De Pascale G; Ait Hssain A
J Clin Med; 2022 Nov; 11(23):. PubMed ID: 36498473
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience.
Richter DC; Frey O; Röhr A; Roberts JA; Köberer A; Fuchs T; Papadimas N; Heinzel-Gutenbrunner M; Brenner T; Lichtenstern C; Weigand MA; Brinkmann A
Infection; 2019 Dec; 47(6):1001-1011. PubMed ID: 31473974
[TBL] [Abstract][Full Text] [Related]
28. β-lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: a structured review.
Sinnollareddy MG; Roberts MS; Lipman J; Roberts JA
Clin Exp Pharmacol Physiol; 2012 Jun; 39(6):489-96. PubMed ID: 22519600
[TBL] [Abstract][Full Text] [Related]
29. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
Burgess DS; Frei CR
J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
[TBL] [Abstract][Full Text] [Related]
30. A systematic review of optimal pharmacokinetic/pharmacodynamic parameters for beta-lactam therapy in infective endocarditis.
Robson C; Tan B; Stuart R; Nicholls S; Rogers BA; Sandaradura I
J Antimicrob Chemother; 2023 Mar; 78(3):599-612. PubMed ID: 36691839
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic/Pharmacodynamic Considerations of Beta-Lactam Antibiotics in Adult Critically Ill Patients.
Masich AM; Heavner MS; Gonzales JP; Claeys KC
Curr Infect Dis Rep; 2018 Apr; 20(5):9. PubMed ID: 29619607
[TBL] [Abstract][Full Text] [Related]
32. Low attainment to PK/PD-targets for β-lactams in a multi-center study on the first 72 h of treatment in ICU patients.
Smekal AK; Furebring M; Eliasson E; Lipcsey M
Sci Rep; 2022 Dec; 12(1):21891. PubMed ID: 36535989
[TBL] [Abstract][Full Text] [Related]
33. PBP Target Profiling by β-Lactam and β-Lactamase Inhibitors in Intact Pseudomonas aeruginosa: Effects of the Intrinsic and Acquired Resistance Determinants on the Periplasmic Drug Availability.
Montaner M; Lopez-Argüello S; Oliver A; Moya B
Microbiol Spectr; 2023 Feb; 11(1):e0303822. PubMed ID: 36475840
[TBL] [Abstract][Full Text] [Related]
34. A Review of Extended and Continuous Infusion Beta-Lactams in Pediatric Patients.
Imburgia TA; Kussin ML
J Pediatr Pharmacol Ther; 2022; 27(3):214-227. PubMed ID: 35350159
[TBL] [Abstract][Full Text] [Related]
35. Continuous Infusion Versus Intermittent Bolus of Beta-Lactams in Critically Ill Patients with Respiratory Infections: A Systematic Review and Meta-analysis.
Lee YR; Miller PD; Alzghari SK; Blanco DD; Hager JD; Kuntz KS
Eur J Drug Metab Pharmacokinet; 2018 Apr; 43(2):155-170. PubMed ID: 29027128
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic and Pharmacodynamic Considerations of Antibiotics of Last Resort in Treating Gram-Negative Infections in Adult Critically Ill Patients.
Heavner MS; Claeys KC; Masich AM; Gonzales JP
Curr Infect Dis Rep; 2018 Apr; 20(5):10. PubMed ID: 29623443
[TBL] [Abstract][Full Text] [Related]
37. Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence.
Viale P; Sandrock CE; Ramirez P; Rossolini GM; Lodise TP
Ann Intensive Care; 2023 Jun; 13(1):52. PubMed ID: 37322293
[TBL] [Abstract][Full Text] [Related]
38. Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis.
Abdul-Aziz MH; Sulaiman H; Mat-Nor MB; Rai V; Wong KK; Hasan MS; Abd Rahman AN; Jamal JA; Wallis SC; Lipman J; Staatz CE; Roberts JA
Intensive Care Med; 2016 Oct; 42(10):1535-1545. PubMed ID: 26754759
[TBL] [Abstract][Full Text] [Related]
39. Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic/pharmacodynamic analysis.
Ehmann L; Zoller M; Minichmayr IK; Scharf C; Huisinga W; Zander J; Kloft C
Int J Antimicrob Agents; 2019 Sep; 54(3):309-317. PubMed ID: 31229669
[TBL] [Abstract][Full Text] [Related]
40. Population pharmacokinetic models of first choice beta-lactam antibiotics for severe infections treatment: What antibiotic regimen to prescribe in children?
Marsot A
J Pharm Pharm Sci; 2020; 23():470-485. PubMed ID: 33227230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
